Page 13 - Galit Alter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By RACHEL LEESON | Ragon Institute Communications Image: NiseriN/iStock/Getty Images Plus This article is part of Harvard Medical School’s of medicine, biomedical research, medical education, and policy related to the SARS-CoV-2 pandemic and the disease COVID-19. Does an infection with SARS-CoV-2 render people protected from subsequent infections with the virus? And if so, how do we know which individuals have built up their immune defenses? These have been two of the most important, and confounding, questions about COVID-19,  and the answers hold valuable clues about t...

The arrival of the COVID-19 vaccine marks a new era in medicine for many reasons, bringing both praise and speculation. The technology involved in its creation, the unprecedented speed of its production and the urgency of its rollout have instigated many questions about its safety and efficacy. In the first of a four-part virtual event series on the COVID-19 vaccine,  CommonHealth reporter  Angus Chen sat down with Galit Alter, professor of medicine at Harvard Medical School and group leader at the Ragon Institute to answer some of these questions. The event began with a crash course on th...

Scientific American Preventing the Next Pandemic An influenza pandemic like that of 1918 could make the scourge of COVID-19 look mild. A vaccine to prevent it may finally be possible. This article was produced for Sabin Vaccine Institute by Scientific American Custom Media, a division separate from the magazine's board of editors. Prototype universal influenza vaccines such as this one, a nanoparticle with a protein scaffold (blue) studded with influenza hemagglutinin proteins (green), could provoke an immune response to all human influenza subtypes. Credit: NIAID  Between 1918 and 1920, th...

National February 6, 2021 LAHORE: Global funding for COVID-19 vaccine development has exceeded 10 times in less than a year the amount allocated for HIV and TB research and development in 11 years. “A staggering amount of $103.8 billion has been thrust into COVID-19 vaccine development within a period of just 11 months of 2020 as compared to a paltry $9.5 billion ($8.5 billion for HIV and $1billion for TB) for HIV and TB research and vaccine development during 11-year period from 2009 to 2019,” according to the statistical data compiled by Treatment Action Group (TAG-USA). “According t...

Embed iframe src "https://www.npr.org/player/embed/957301807/961970056" width "100%" height "290" frameborder "0" scrolling "no" title "NPR embedded audio player" SARAH MCCAMMON, HOST: Many countries are finding it difficult to get hold of the vaccines they want. Take Argentina, its efforts to go with the Pfizer vaccine broke down and it's now turned to a controversial Russian vaccine called Sputnik V. NPR's Jason Beaubien has more. JASON BEAUBIEN, BYLINE: To understand Argentina's rush to authorize the Sputnik V vaccine, which hasn't yet won authorization from any major regulator, you ha...